Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Shares of Novavax Inc. NVAX shed 2.37% to $6.19 Tuesday, on what proved to be an all-around mixed trading session for the ...

Novavax Inc (NVAX) reports a dramatic revenue increase and strategic collaborations, while navigating regulatory hurdles and ...

Novavax is undervalued, presenting an attractive risk-reward profile for long-term investors. Click here to find out why NVAX ...

Novavax (NVAX) stock jumps 35% as the company raises its 2025 revenue outlook and its Q1 2025 financials surpasses forecasts ...

Novavax on Thursday tried to calm investors spooked by the delay of full approval of its COVID vaccine shot by U.S.

Shares of Novavax Inc. NVAX rallied 6.11% to $6.34 Monday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ Composite Index COMP rising 4.35% to ...

Analysts are estimating that Novavax will report an earnings per share (EPS) of $0.19. The market awaits Novavax's ...

NVAX should be on investors' short list. Should You Invest in Novavax, Inc. (NVAX)? Before you invest in Novavax, Inc. (NVAX), want to know the best stocks to buy for the next 30 days? Check out ...

NVAX boasts a Momentum Style Score of B and VGM Score of B, and holds a Zacks Rank #3 (Hold) rating. Shares of Novavax has seen some interesting price action recently; the stock is up 3.9% over the ...